Silence Therapeutics (NASDAQ:SLN) Earns Overweight Rating from Morgan Stanley

Silence Therapeutics (NASDAQ:SLN)‘s stock had its “overweight” rating reiterated by equities researchers at Morgan Stanley in a report released on Monday, Benzinga reports. They currently have a $45.00 price objective on the stock. Morgan Stanley’s target price points to a potential upside of 99.91% from the stock’s previous close.

Several other analysts have also recently issued reports on SLN. HC Wainwright reissued a “buy” rating and set a $75.00 price objective on shares of Silence Therapeutics in a research note on Friday, March 15th. BMO Capital Markets began coverage on shares of Silence Therapeutics in a research note on Wednesday, January 31st. They set an “outperform” rating and a $67.00 price objective for the company. Finally, Chardan Capital upped their price target on shares of Silence Therapeutics from $26.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, March 14th.

Silence Therapeutics Stock Up 0.0 %

SLN stock opened at $22.51 on Monday. The stock has a market capitalization of $673.72 million, a P/E ratio of -15.42 and a beta of 1.41. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.56 and a current ratio of 4.56. Silence Therapeutics has a one year low of $4.55 and a one year high of $27.72. The company has a 50 day moving average price of $23.02 and a two-hundred day moving average price of $17.34.

Silence Therapeutics (NASDAQ:SLN) last announced its quarterly earnings data on Wednesday, March 13th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.22). Silence Therapeutics had a negative net margin of 171.41% and a negative return on equity of 262.17%. The company had revenue of $2.61 million for the quarter, compared to analysts’ expectations of $11.46 million. As a group, sell-side analysts expect that Silence Therapeutics will post -1.38 EPS for the current year.

Hedge Funds Weigh In On Silence Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Lynx1 Capital Management LP acquired a new position in Silence Therapeutics in the 3rd quarter worth $2,315,000. SG Americas Securities LLC acquired a new position in Silence Therapeutics in the 4th quarter worth $110,000. Parkman Healthcare Partners LLC lifted its holdings in Silence Therapeutics by 20.8% in the 4th quarter. Parkman Healthcare Partners LLC now owns 232,942 shares of the company’s stock worth $4,046,000 after buying an additional 40,063 shares in the last quarter. Finally, Vivo Capital LLC acquired a new stake in shares of Silence Therapeutics in the 4th quarter valued at about $8,862,000. Institutional investors and hedge funds own 98.73% of the company’s stock.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.